Zobrazeno 1 - 1
of 1
pro vyhledávání: '"JC Tallón Martínez"'
Autor:
I Larrosa Espejo, JM Martínez Sesmero, JC Tallón Martínez, G Hernando Llorente, Zamora Barrios, E Roson Sanchez, M Molinero Muñoz, M.P. Pacheco Ramos, C González-Pérez, A. Arenaza Peña
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Between 2016 and 2017 the National Agency of Medicines and Medical Devices regulated the use of nivolumab and pembrolizumab for the treatment of non-small-cell lung cancer (NSCLC). In clinical trials conducted, patients with ECOG 0–1 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b096b757c9604eedb7bb0532c48eebd
https://doi.org/10.1136/ejhpharm-2019-eahpconf.277
https://doi.org/10.1136/ejhpharm-2019-eahpconf.277
